Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Olumiant Up for PAFSC Review for COVID-19 on April 21, Combo Use with Veklury
April 15, 2021
- Drug Pricing Rules to Be Applied to Breyanzi: Chuikyo
April 15, 2021
- Yescarta to Join NHI Price List on April 21, Gets CEA-Tweak from Get-Go
April 14, 2021
- Kymriah to Get 4.3% Reduction, Trelegy 0.5% Cut in 1st CEA-Based Price Tweak
April 14, 2021
- 11 APIs to Get NHI Price Listing on April 21, 17 Billion Yen Peak Sales Projected for Lilly’s Migraine Med
April 14, 2021
- Novo’s Growth Hormone, Fujimoto’s Hemophilia Med Skip April Listing
April 14, 2021
- Japan to Prioritize Screening for N501Y Variant; E484K “Does Not Render Vaccines Ineffective”: Minister
April 14, 2021
- LDP Pharma Study Group to Discuss R&D Support, Eyes Proposal
April 13, 2021
- Kymriah to Face 4% Price Cut in 1st CEA-Based Price Tweak, Yescarta Too
April 13, 2021
- COVID-19 Vaccine Reactions More Common in Women, Younger People: MHLW Study
April 12, 2021
- Vaccine Safety Panels to Evaluate Suspected Anaphylaxis Cases Based on Pfizer’s Reports
April 12, 2021
- Development of Japan-Made Vaccines “Significantly Meaningful”: Minister
April 12, 2021
- MSD’s Recarbrio Up for PAFSC Review on April 21
April 8, 2021
- Label Update Will Suffice to Expand COVID-19 Vaccination Age: MHLW Official
April 7, 2021
- AMED to Set Up Council to Hone Academic Seeds with Industry Input
April 7, 2021
- MHLW Launches New Office to Fuel SaMD Commercialization
April 6, 2021
- MHLW to Consider Ways to Address Listing Delays Linked to Off-Year Re-Pricing: Official
April 6, 2021
- Nichi-Iko’s Toyama Plant Gets Back Online as Suspension Order Lifted
April 6, 2021
- 1st Vaccine Doses to Be Delivered for Half of Elderly by May: Kono
April 5, 2021
- Ex-PMDA Inspector Urges Improvements in Japanese Inspection Systems after GMP Scandals
April 5, 2021
ページ
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…